Abstract: Provided is a therapeutic agent for a degenerative neuronal disease, and more particularly, a composition containing, as an active ingredient, an inhibitor of anaplastic lymphoma kinase (ALK) activity of expression for treating a degenerative neuronal disease caused by aggregation and phosphorylation of tau protein.

Abstract: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-? (A?) to Fc?RIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an Fc?RIIb protein or a variant thereof, an Fc?RIIb extracellular domain, an anti-Fc?RIIb antibody, an Fc?RIIb-specific peptide and an Fc?RIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of A? and the neurotoxicity, neuronal cell death and memory impairment mediated by A? by inhibiting the binding between A? and Fc?RIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.

Abstract: Provided is a therapeutic agent for a degenerative neuronal disease, and more particularly, a composition containing, as an active ingredient, an inhibitor of anaplastic lymphoma kinase (ALK) activity of expression for treating a degenerative neuronal disease caused by aggregation and phosphorylation of tau protein.

Abstract: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-? (A?) to Fc?RIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an Fc?RIIb protein or a variant thereof, an Fc?RIIb extracellular domain, an anti-Fc?RIIb antibody, an Fc?RIIb-specific peptide and an Fc?RIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of A? and the neurotoxicity, neuronal cell death and memory impairment mediated by A? by inhibiting the binding between A? and Fc?RIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.

Abstract: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-? (A?) to Fc?RIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an Fc?RIIb protein or a variant thereof, an Fc?RIIb extracellular domain, an anti-Fc?RIIb antibody, an Fc?RIIb-specific peptide and an Fc?RIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of A? and the neurotoxicity, neuronal cell death and memory impairment mediated by A? by inhibiting the binding between A? and Fc?RIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.

Abstract: Disclosed herein are methods of diagnosing, preventing and treating Alzheimer's disease based on the use of an inhibitor for the binding of amyloid-? (A?) to Fc?RIIb, and a method of screening the inhibitor. The inhibitor is selected from the group consisting of an Fc?RIIb protein or a variant thereof, an Fc?RIIb extracellular domain, an anti-Fc?RIIb antibody, an Fc?RIIb-specific peptide and an Fc?RIIb-specific siRNA. The inhibitor reduces the toxic signaling and intracellular translocation of A? and the neurotoxicity, neuronal cell death and memory impairment mediated by A? by inhibiting the binding between A? and Fc?RIIb. Thus, the inhibitor is useful in the diagnosis, prevention and treatment of Alzheimer's disease.